ABSTRACT

This review’s objective is to update methodologies for spectrophotometric and chromatographic measurement of Ritonavir and Nirmatrelvir in pharmaceutical dosage forms that are used in viral infection. It implies different analytical procedures like UV, HPLC, RP HPLC, LC-MS, HPTLC, and other methods reported till date. There are numerous articles that describe the analytical process for the same that have been already published. An FDA-approved novel co-packaged drug called nirmatrelvir plus ritonavir has been developed to treat COVID-19. This review provides a summary of the work done on Ritonavir and Nirmatrelvir alone or in combination with or without the presence of impurities and their degradation products. Keywords: Ritonavir, Nirmatrelvir, Antiviral agent, HPLC, LC-MS
Publication date: 01/04/2025

https://ijbpas.com/pdf/2025/April/MS_IJBPAS_2025_8911.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2025/14.4.8911